For Global Porphyria Day, we heard from people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) about their condition and unmet needs. Learn more at United Porphyrias Association & GlobalPorphyria and listen to their stories: bit.ly/3QQkP1g #MyPorphyria

In partnership with Medscape, we launched a medical education tool on the clinical advances in transthyretin amyloid cardiomyopathy (ATTR-CM). We hope this provides supportive resources for physicians to understand the changing landscape of this disease. bit.ly/48ugdnx

At the 2024 FDLI Conference, Darcy Frear, Ph.D., our associate director of regulatory policy & intel will be speaking about best practices to proactively engage with regulators to best meet the needs of patients with rare & neurodegenerative diseases.

Such an amazing chance to catch up with leaders in cardiology and learn about innovative developments for patients with heart conditions like ATTR-CM at this year’s @ESCardio Heart Failure!

Tomorrow, we’ll be presenting at the Bank of America Merrill Lynch Global Healthcare Conference. Join and learn more about our mission to develop meaningful medicines for people with genetic diseases and cancers. Read more: bit.ly/3WDXy6c

Excited to share a sub-analysis comparing acoramidis to placebo in Stage 4 chronic kidney disease & results from a pre-specified sensitivity analysis from ATTRibute-CM, our Phase 3 study of acoramidis in ATTR-CM, & 3 posters at @ESCardio Heart Failure. bit.ly/4dE9zPm

We're grateful to all of the mothers we interact with: the ones persevering as patients, the ones caring and advocating for their loved ones, the ones creating therapies for those in need, and the ones who inspire us every day. Happy Mother's Day!

In part 2 of our #OnRare episode with Eric, we hear more about his experience living with transthyretin amyloidosis (ATTR). He explains how impactful becoming involved with the ATTR community has been for himself and others. Listen here: bit.ly/46IBOYm

We’re thrilled to support a Satellite Symposium with leading cardiologists onsite at @ESCardio Heart Failure on a deep dive into the health-related quality of life (HRQoL) in patients with ATTR-CM. Learn more about the discussion here: bit.ly/3UiLYuw #jointheconversation

At this year’s @ESCardio Heart Failure, we will be presenting a sub-analysis in CKD from ATTRibute-CM, our Phase 3 study in patients with ATTR-CM as well as sharing moderated posters on data from the trial. Join us onsite to learn more.

At European Society of Endocrinology (ESE) 2024, we will be sharing 18-month results from our Phase 2 study in ADH1, details on our study design for CALIBRATE, the first Phase 3 study of encaleret for adults with ADH1, and insights from our genetic testing program. bit.ly/3LPOvt9 #ECE2024

We're heading to @ESCardio Heart Failure! This year, we'll be sharing updates from our ATTRibute-CM Phase 3 trial in 1 oral presentation & 3 moderated poster presentations & supporting a Satellite Symposium. Learn more about our latest news: bridgebio.com/what-is-attr

Our BridgeBio Gene Therapy team was proud to accept the Corporate Partner Award at the @CARESfoundation Gala. Thank you, CARES Foundation, for inviting us to be part of the event and for the honor, our ongoing partnership, and your service to the CAH community!

We're grateful for the opportunity to hear & learn from the porphyria community, specifically those with erythropoietic protoporphyria and x-linked protoporphyria, about their experience living with their condition & the unmet needs of the community. #myporphyria

At this year’s @Asembia Specialty Pharmacy Summit, BridgeBio will be supporting a satellite symposium with ReachMD to provide educational tools for navigating the evolving landscape in ATTR-CM. Register here: bit.ly/43Sknot

At the World Orphan Drug Congress Congress this week, Douglas Sproule M.D., M.Sc., CMO of our limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) program will be on a panel to discuss how to facilitate drug development in rare diseases. bit.ly/3W21pKi